25 Oct 2022
Scancell Holdings plc
("Scancell" or the "Company")
Scancell signs Commercial License Agreement with Genmab
Genmab granted worldwide license to anti-glycan monoclonal antibody generated via Scancell's proprietary GlyMab® platform, for the development and commercialisation of novel therapeutic products
Scancell to receive from Genmab an upfront payment as well as potential milestone payments of up to $208 million for each product... Read more